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Abstract
Background: Hepatitis B virus (HBV) DNA levels are crucial for managing chronic hepatitis B (CHB). It was unclear
whether Daan real-time polymerase chain reaction test (Daan test) or COBAS TaqMan HBV DNA Test (Cobas
TaqMan) was superior in measuring different HBV DNA levels in clinical specimens.
Methods: We enrolled 67 treatment-naïve, HBV surface antigen-positive CHB patients (high baseline viral levels)
who received either lamivudine/adefovir or entecavir. Serum samples were tested at baseline and treatment week
24 using the Daan test and Cobas TaqMan.
Results: In the 67-baseline samples, the HBV DNA levels with the Cobas TaqMan (7.90 ± 0.73 log10 IU/mL) were
significantly greater than those of the Daan test (7.11 ± 0.44 log10 IU/mL; P < 0.001). Of the 67 24-week samples (low
viral levels), the Cobas TaqMan detected 59 (88.1%; 8 undetected); the Daan test detected 33 (49.3%; 34 undetected;
P < 0.001). The Cobas TaqMan detected HBV DNA in 26 of 34 samples undetectable by the Daan test (range, 1.4–3.7
log10 IU/mL) or 38% of samples (26/67). The reductions in viral load after 24 weeks of oral antiviral treatment in the
33 samples that were positive for both the Daan test and the Cobas TaqMan test were significantly different (3.59 ±
1.11 log10 IU/mL versus 4.87 ± 1.58 log10 IU/mL, respectively; P = 0.001). Spearman correlation analysis showed positive
correlation between results from two tests (rp = 0.602,P<0.001). The HBV genotypes and the anti-viral treatment did not
affect the measurements of the HBV DNA by the Daan assay and the Cobas Taqman assay.
Conclusion: The Cobas Taqman was more sensitive at low viral loads than the Daan test and the change from complete
to partial virological response could affect clinical decisions. The Cobas Taqman may be more appropriate for detection of
HBV DNA levels.
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Background
Chronic hepatitis B (CHB) and its chronic sequelae (e.g.,
cirrhosis and hepatocellular carcinoma (HCC)) are major
health problems, especially in Asia [1,2]. Detecting hepa-
titis B virus (HBV) DNA, a marker of viral replication,
strongly indicates evidence of an HBV infection, as HBV
surface antigen (HBsAg) is detected [3,4]. The detection
of HBeAg is important, as its presence usually indicates
active HBV replication and a higher risk for HCC [5].
Also, the presence of HBeAg may imply an earlier phase
or an active infection with HBV [2].
A goal of CHB therapy is to persistently suppress HBV
replication [6]. Efficacy of treatment for CHB ranges from
17% to 53% [7-9], and is hindered by the development of
HBV resistance to ongoing therapy [10]. Measurement of
HBV DNA levels is the most direct and effective way to
assess HBV management and high HBV DNA levels are
risk factors for development of fibrosis, cirrhosis, hepato-
cellular carcinoma, and drug resistance [11]. Since fluctua-
tions in HBV DNA levels often trigger a modification in
the patients’ treatment regimen, the accuracy and detec-
tion limits of the methods that quantitate HBV DNA
levels can influence the clinical decision making process,
* Correspondence: pjie138@163.com
1NanFang Hospital, Southern Medical University, Guangzhou, Guangdong
Province, China
Full list of author information is available at the end of the article
© 2014 Cai et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
Cai et al. BMC Infectious Diseases 2014, 14:85
http://www.biomedcentral.com/1471-2334/14/85
including the dosage, the schedule, and subsequently
monitoring of CHB patients [12-15]. Yuan and colleagues
[13] found that only 38% of serum samples (161 of 425) of
Chinese CHB patients had detectable HBV DNA levels by
a liquid hybridization method (Digene Hybrid Capture II
test (Digene test; Digene, Gathersburg, MD, USA); but
HBV DNA levels were detected in 89% of these samples
(383/425) by the real-time polymerase chain reaction
(PCR) method, Cobas TaqMan assay (Cobas TaqMan,
Roche Molecular Systems, Inc., Branchburg, NJ). Cur-
rently, real-time PCR quantification assays are used for
measuring HBV DNA due to their sensitivity, specificity,
and dynamic range [12,16,17]. Accuracy is enhanced when
the HBV DNA is assayed within a linear range [3,13,16].
Comparison of the accuracy and detectable range between
the different PCR tests suggest that the Cobas TaqMan
assay (Cobas TaqMan) shows similar sensitivity and speci-
ficity rates to the RealArt assay (Abbott, North Chicago,
IL USA) [3].
However, to our knowledge, comparisons between the
Cobas TaqMan assay and the Daan test of HBV DNA
levels have not been performed with clinical samples
from patients with both high and low viral loads, par-
ticularly those from posttreatment patients who may
have very low viral loads. In this multicenter, prospect-
ive, cohort study, we aimed to investigate any potential
differences in detecting HBV DNA levels between the 2
methods in a clinical setting by testing samples with
high or low viral loads taken from Chinese carriers at
baseline and after 24 weeks of oral antiviral treatment.
Methods
Subjects
This study was a multicenter prospective cohort study.
From July, 2011 to March, 2012, we enrolled a cohort of 67
treatment-naive patients (48 males, 19 females), who were
diagnosed with hepatitis B virus e antigen (HBeAg)-positive
CHB with high viral loads at baseline. Of the 67 patients,
eight patients were from Southwest Hospital, six patients
were from Sir Run Run Shaw Hospital, eighteen patients
were from Second Xiangya Hospital, and the remaining
thirty-five patients were from NanFang Hospital. The in-
clusion criteria were HBeAg-positive CHB with high viral
loads at baseline (HBsAg positive >6 months; serum HBV
DNA levels >2 × 106 log10 IU/mL by the Daan test). HBeAg
was positive by radioimmunoassay (Abbott Laboratories).
We also included patients who had alanine aminotransfer-
ase (ALT) levels greater than the upper limit of normal
(ULN), documented on 2 separate occasions 2 weeks apart,
with the latest ALT ≥ 2 ×ULN. Exclusion criteria were evi-
dence of cirrhosis or coinfections with any other viruses,
such as hepatitis C virus or human immunodeficiency virus
(HIV), or presence of autoimmune hepatitis, alcohol liver
disease, or hepatocellular carcinoma.
The Institutional Review Board of Nanfang Hospital,
Southern Medical University of the participating sites
had approved the study to compare the sensitivity and
range of the two assays, Daan test and Cobas PCR test.
Each enrolled patient provided informed consent. Pa-
tients were treated with entecavir (ETV) or the combin-
ation lamivudine (LAM) plus adefovir (ADV), according
to the Chinese guidelines; tenofovir disopril fumarate
was not available in China. Because patients may have
used economic considerations to choose drug treatment,
the drug treatment was not randomized. Forty-one
(61.2%) of the sixty-seven patients received oral antiviral
treatment with LAM plus ADV combination therapy,
and the remaining twenty-six patients received entecavir
(ETV) monotherapy. Blood samples were obtained at
baseline and at week 24 and serum samples were col-
lected. All samples were aliquoted and stored immedi-
ately at –80ºC.
Quantification of serum HBV DNA and determination of
HBV genotype
The Daan test was performed at the Nanfang Hospital
per the manufacturer’s instructions (Daan Gene Co, Ltd
of Sun Yat-sen University, Guangdong, China). Briefly,
HBV DNA was extracted with control DNA from
100 μL of serum and detected by PCR fluorescence
probing. The real-time PCR assay was performed in
the Roche LightCycler 480 (Roche Diagnostics Ltd,
Switzerland) according to the manufacturer’s instruc-
tions; the PCR amplification reaction used thermus
aquaticus DNA polymerase, deoxyribonucleoside tri-
phosphates (dNTPs), and a HBV DNA specific probe to
detect and measure serum HBV DNA levels. The manu-
facturer reports a linear range of 1 × 102 IU/mL to 1 ×
108 IU/mL.
The Cobas TaqMan assay was performed at the Nan-
fang Hospital according to the manufacturer’s instruc-
tions (Roche Molecular Systems, Inc, Pleasanton, CA,
USA). The Cobas TaqMan assay is based on the co-
amplification of target HBV DNA and the detection of a
cleaved dual-labeled oligonucleotide detection probe
specific to the target. Serum samples of 750 μL were
transferred for automatic processing. The manufacturer
reports a HBV DNA linear range of 20 IU/mL to 1.7 ×
108 IU/mL.
The HBV genotype was determined by nested PCR
with the Qiagen Mini Kit (Qiagen), following the manu-
facturer’s instructions.
Follow-up
The enrolled patients were seen from July 2011 to
September 2012 in 1 of 4 teaching hospitals—Nanfang
Hospital of Southern Medical University in Guangzhou
(43 patients), the Second Xiangya Hospital of Central
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South University in Changsha (13 patients), the Affiliated
Sir Run Run Shaw Hospital of Zhejiang University in
Hangzhou (3 patients), or Southwest Hospital of the Third
Military Medical University in Chongqing (8 patients).
Serum ALT (Olympus AU5400) and HBeAg levels (radio-
immunoassay) were assessed at week 12. At week 24,
serum ALT, HBeAg, and HBV DNA levels were evaluated.
Virological responses were scored according to the
guidelines recommended by the European Association
for the Study of the Liver (EASL) for nucleos(t)ide ana-
logues (NAs) therapy [6].
Statistical analysis
Mean and standard deviation (SD) were calculated for
continuous variables, and percentages were used for cat-
egorical variables. Levels of quantified HBV DNA levels
were expressed in logarithmic units (log10 IU/mL). HBV
DNA levels with the Cobas TaqMan were assigned as
negative, if results were below 20 IU/mL and thus were
considered to be undetectable values. To determine
whether the results were statistically different, the χ2
test, the t test, and the Spearman correlation coefficient
were applied, as appropriate. For each pair of measure-
ments, the agreement between the Cobas TaqMan and
the Daan test were plotted against their means in a
Bland-Altman analysis. The statistical significance of all
tests was defined as P < 0.05 by 2-tailed tests. Quality
control procedures, as well as data analyses, were per-
formed by using MedCalc for Windows, version 9.38
(MedCalc Software, Mariakerke, Belgium).
Results
Demographics
Sixty-seven treatment-naïve patients (48 male, 19 fe-
male) who were diagnosed with hepatitis B virus e anti-
gen (HBeAg) positive CHB with high viral load at
baseline from July 2011 to March 2012 were enrolled in
a multicenter prospective trial. The mean age was 30.6 ±
8.4 years (range: 16 to 61 years) (Table 1). HBV genotype
B was found in 43 patients (64.2%, all B2 subgenotype)
and HBV genotype C was found in 24 patients (35.8%;
17 with subgenotype C1 and 7 with C2 subgenotype).
Forty-one out of the 67 patients (61.2%) received oral
antiviral treatment with de novo lamivudine (LAM)
and adefovir (ADV) combination therapy and 26 patients
received entecavir (ETV).
Virological responses
The results from the Daan test indicated that 34 patients
(50.7%) achieved virological responses and 33 patients
(49.3%) attained partial virological responses. The HBV
DNA levels obtained by the Cobas TaqMan assay indi-
cated that 8 patients (11.9%) patients had virological re-
sponses and 58 patients (86.6%) had partial virological
responses. Thus, the clinical assessments of the 34 sam-
ples by the two assays were significantly different (P <
0.001). In particular, 1 study patient who was classified
as a partial virological responder by the Daan Test was
classified as a primary non-responder by the Cobas Taq-
Man assay. Therefore, this comparison indicates that the
more sensitive assay can alter clinical decisions and is
crucial for managing CHB patients.
Comparison of assays for measuring high HBV viral load
in clinical samples
The HBV DNA levels of the 67 serum samples at base-
line showed a high viral load and were detected by both
the Cobas TaqMan and the Daan tests. All 67 baseline
serum samples were quantitated by the Daans test
whereas 27 of 67 of these baseline samples needed to be
diluted for quantification by the Cobas TaqMan test (17
samples had HBV B genotype and 10 samples C geno-
type). The differences in the viral load of the 27 samples
ranged from < 0.5log10 IU/mL in 3 samples (11.1%) to
between 0.5log10 IU/mL and 1log10 IU/mL in 10 samples
(37.0%) to ≥1 log10 IU/mL in 14 samples (51.9%). Forty
samples were measured without dilution by the Cobas
TaqMan test (26 had B genotype and 14 had C geno-
type). Genotypes were not significantly different at base-
line viral load (p = 0.87).
The mean baseline viral load of patients treated with
LAM/ADV and assessed by Cobas TaqMan (8.02 ±
0.57log10 IU/mL) was significantly higher than those
assessed by Daan test (7.01 ± 0.43log10 IU/mL; P <
0.001). Likewise, the mean baseline viral load of patients
treated with ETV assessed with the Cobas TaqMan (7.71 ±
0.90log10 IU/mL) was significantly greater than those
assessed by the Daan test (7.13 ± 0.46log10 IU/mL; P =
0.002). Thus, HBV DNA levels with the Cobas TaqMan
Table 1 Demographic and virologic characteristics of the
study patients
n = 67





Lamivudine plus adefovir 41 (61.2)
Entecavir 26 (38.8)
ALT (IU/mL)a 202.9 ± 137.9
HBV DNA (log10 IU/mL)
Daan Testa,b 7.11 ± 0.44
Cobas TaqMana,b 7.90 ± 0.73
aThe value is expressed as mean ± SD.
bThe value is expressed after logarithmic transformation (log10 IU/mL).
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were significantly greater than that of the Daan Test
(7.90 ± 0.72 log10 IU/mL versus 7.11 ± 0.44 log10 IU/mL,
respectively; P < 0.001). Of note, the level of high viral load
(≥7 log10 IU/mL) detected by the Cobas TaqMan test
(8.09 ± 0.43) significantly differed from that of the Daan
test (7.14 ± 0.43) (P < 0.001).
Comparison of assays for measuring low HBV viral load
(week 24 posttreatment clinical samples)
Another 67 serum samples were obtained from the pa-
tients at week 24 post treatment: the HBV DNA levels
of only 33 clinical samples were detected by both assays.
No significant differences were observed between the
average HBV DNA levels with the Cobas TaqMan assay
(3.25 ± 1.37 log10 IU/mL; range, from 1.34 log10 IU/mL
to 6.41 log10 IU/mL) of these 33 posttreatment samples
and those determined with the Daan test (3.52 ± 0.97
log10 IU/mL; range, from 2.20 log10 IU/mL to 6.86 log10
IU/mL) (P = 0.19). The correlation coefficient for the
HBV DNA levels in these 33 samples detected by these
two assays was 0.56 (Spearman correlation, P = 0.001).
The divergence in the HBV DNA levels between both
assays was within 0.5 log10 IU/mL and was found in only
10 samples.
The Cobas TaqMan test detected HBV DNA levels in
59 of the 67 week 24 serum samples (88.1%) whereas
the Daan test detected HBV DNA levels in 33 of the
67 week 24 serum samples (49.7%)( P < 0.001). Thus,
the Cobas TaqMan test quantitated HBV DNA levels in
26 of the 34 serum samples that had HBV DNA levels
below the linear range of Daans test. The minimal value
of these 26 samples was 1.44log10 IU/mL, the maximal
value was 3.66log10 IU/mL, and the mean was 2.15 ±
0.58 log IU/mL.
The 24 week patient samples that tested positive by
Cobas TaqMan showed no marked difference in HBV
genotypes: HBV genotype B was present in 83.72% of
samples and C in 95.83% samples, (P = 0.14). The patient
samples that tested positive by Daans also showed no
significant difference among genotypes: 44.2% of samples
contained HBV genotypes B and 58.33% contained HBV
genotype C (P = 0.26). Multivariate Analysis of Variance
(MANOVA) was employed to analyze the HBV DNA
determined by Cobas TaqMan assay and Daan test. Re-
sults showed HBV genotypes had no influence on the
HBV DNA level (P = 0.471).
The mean reduction of viral load from baseline to
samples after 24 week treatment with LAM/ADV or
ETV was not significantly different between the two as-
says. The mean reduction of viral load in LAM/ADV
group by the Cobas TaqMan (5.47 ± 1.53log IU/mL) was
similar to that by the Daan test (5.32 ± 1.96log10 IU/mL;
P = 0.57). The mean reductions of viral load in the ETV
group after 24 weeks assessed by the Cobas TaqMan
(5.20 ± 1.17log10 IU/mL) was similar to that assessed by
the Daan test (29 ± 1.83log10 IU/mL; P = 0.8).
Association analyses between the Cobas TaqMan assay
and the Daan test
The HBV DNA levels of the 100 positive samples of the
134 (67 at baseline; 67 at week 24) samples detected by
the Daan test were well correlated to those detected by
the Cobas TaqMan (rp = 0.79; P < 0.001; Figure 1). The
reductions in viral load after 24 weeks of oral antiviral
treatment in the 33 samples that were positive for both
the Daan and the Cobas TaqMan tests were significantly
different (3.59 ± 1.11 log10 IU/mL versus 4.87 ± 1.58
log10 IU/mL, respectively; P = 0.001). Spearman correl-
ation analysis showed positive correlation between re-
sults from two tests (rp = 0.602,P<0.001). However,
according to the results from the Daan test, 34 patients
(34/67; 50.7%) had undetectable HBV DNA levels, and
33 patients (33/67, 49.3%) had decreases in HBV DNA
levels of more than 1 log10 IU/mL from baseline (but
were still detectable) after 24 weeks on treatment. In
comparison, the results of the Cobas TaqMan test indi-
cated that 8 patients (8/67; 11.9%) had undetectable
HBV DNA levels, and 58 patients (58/67; 86.6%) showed
decreases in HBV DNA levels of more than 1 log10
IU/mL (but were still detectable) after 24 weeks on
therapy (P < 0.001). A reduction of HBV viral load in
one patient (1/67; 1.5%) varied from 1.38 log10 IU/mL
with the Daan Test to –0.42 log10 IU/mL with the
Cobas TaqMan.
Agreement analyses between the Cobas TaqMan assay
and the Daan test
A Bland-Altman plot was used to visualize the differ-
ences between HBV DNA quantitation of both baseline and
posttreatment serum samples (n = 134) by the two methods
(Figure 2). At baseline, the mean difference between the
Cobas TaqMan assay and the Daan test was −0.79 log10
IU/mL, with limits of agreement from −2.20 log10 IU/mL
to 0.63 log10 IU/mL. The HBV DNA levels in the baseline
high viral loads (>106 IU/mL) determined with the Daan
test were lower than those determined by the Cobas
Taqman test. In contrast, at 24-week postteatment, the
Cobas TaqMan and the Daan test showed good agreement
on low viral load HBV DNA levels, with the mean
difference of –0.3 log10 IU/mL and with limits of
agreement from −2.6 log10 IU/mL to 2.1 log10 IU/mL.
Discussion
The HBV DNA levels from the 134 samples detected by
both the Daan test and Cobas TaqMan were, in general,
concordant. The HBV genotypes and the anti-viral ther-
apy did not significantly affect the measurement of the
viral loads by either the Daan or the Cobas Taqman
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assays. However, through further stratified analyses that
accounted for the significant differences in the high viral
load samples (>7 log10 IU/mL), we conclude that the
Cobas TaqMan assay was superior to that of the Daan
test. Therefore, it might be necessary to reconsider the
usage of the Daan test because the Daan test was not as
sensitive in detecting and quantifying HBV DNA levels
as the Cobas TaqMan test in our study.
Serum HBV DNA levels are key indicators for CHB
management, including assessing treatment initiation,
treatment response, and drug withdrawal [6,18]. A more
effective and sensitive method to detect HBV DNA
levels could assist in improving key medical decisions
and clinical patient management [19]. Current studies
have demonstrated that monotherapy with a high resist-
ance barrier agent or de novo combination therapy is a
more appropriate choice for CHB patients with high
baseline HBV DNA levels, as the risk of resistance and
treatment failure are associated with high viral loads
[20]. In order to avoid the emergence of drug resistant
HBV [21,22], HBV DNA levels should be confirmed as
early as possible. According to the results of the current
study, viral load monitoring and HBV DNA detection
were superior using the Cobas TaqMan assay to identify
Figure 1 The correlation of 2 methods in a total of the hundred positive of the 134 samples. The Spearman’s correlation coefficient in
HBV DNA level between the 2 methods was rp = 0.79 (P < 0.001).
Figure 2 A Bland–Altman plot of the Cobas TaqMan assay and Daan test at baseline and 24 weeks post treatment.
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a virological response, a partial virological response, or a
primary non-response.
Drug withdrawal is another key problem in CHB man-
agement. According to the most recently proposed
guidelines, treatment withdrawal could be considered if
the HBV DNA levels remained undetectable for at least
12 months, as documented on 2 separate occasions,
which were 6 months apart, in HBeAg-positive patients.
The treatment for HBeAg-negative patients would be
continued for at least 18 months, if undetectable HBV
DNA levels could be documented on 3 separate occa-
sions, which were 6 months apart [6,18,23]. Due to the
significant differences in the undetectable rates in the
low viral load samples between the Daan test and the
Cobas TaqMan assay (50.7% versus 11.9% respectively,
P < 0.001), we believe it is necessary to measure the
HBV DNA levels with the Cobas TaqMan assay to further
confirm if the HBV DNA levels are negative, even if the
HBV DNA levels were undetectable by the Daan test.
This study had a few limitations. This study had a
small sample size, which may limit the generalizability of
the current findings. Further research which utilizes stat-
istical analyses to determine an appropriate sample size
for sufficient statistical power is warranted to validate
the current findings. Additionally, we only examined the
HBV DNA levels at baseline and at 24 weeks. As such,
we suggest additional examinations using these 2 tests at
different times with larger sample sizes. Furthermore,
more comprehensive studies with multiple detections by
these same 2 kits are needed to confirm reproducibility
and to determine if the Cobas TaqMan assay may de-
serve a greater priority than that of the Daan Test. Be-
cause the cost of the Cobas Taqman (500 yen) is greater
than the Daan test (160 yen), a cost-benefit analysis also
would be useful.
Conclusions
Our results show that the Cobas TaqMan assay was
more sensitive in detecting viral loads than the Daan
test. Therefore, we do not think physicians should re-
place the Cobas TaqMan assay with the Daan real-time
PCR test in terms of accurate quantitation. In particular,
at moments of critical decisions, such as treatment initi-
ation, switch of regimens, judgment of treatment efficacy
and treatment cessation, the Cobas TaqMan test should
be the first choice. This is because in some cases, the
HBV DNA level may be lower than the detection limit
of the Daan test, and the change from complete to par-
tial virological response can affect clinical decisions.
However, given the low cost of the Daan test, physi-
cians may consider using this method to monitor disease
progression of patients during the immune-tolerant
phase and of HBeAg positive patients for their mid to
high HBV DNA levels.
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